This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D67 (hereditary factor IX deficiency) | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Plasma Thromboplastin Component deficiency (PTC deficiency), Christmas disease, Hemophilia B, Hereditary factor IX deficiency |
| C. Adult onset | Likelihood of first onset in adulthood: not low — in mild cases of PTC deficiency (= hemophilia B), there are no symptoms without surgery, tooth extraction, or trauma, so cases first discovered in adulthood are common; this term is currently used mainly in historical and literature contexts. |
| 1. History | Origin of the PTC name, simultaneous naming by Aggeler and Biggs in 1952, the TGT test, unification under the Roman numeral system |
| 2. Causes | F9 gene (Xq27.1) mutations, X-linked recessive, diverse variant types |
| 3. Genetics | F9 Xq27.1, 34kb, 8 exons, 415aa, 55kDa, vitamin K-dependent |
| 4. Epidemiology | 1/25,000–30,000 male births, about 160,000 people worldwide, 30% severe |
| 5. Pathophysiology | Impaired function of the FIXa-FVIIIa tenase complex, insufficient FXa generation |
| 6. Symptoms | Hemarthrosis, muscle hematomas, intracranial hemorrhage (severe); bleeding after trauma (mild) |
| 7. Signs | Prolonged APTT, decreased FIX:C, normal PT, inhibitors in 3–5% |
| 8. Screening | APTT → FIX:C → F9 gene analysis, precautions for newborn screening |
| 9. Diagnosis | FIX:C measurement, F9 gene analysis, severity classification, inhibitor testing |
| 10. Treatment | FIX concentrates (SHL, EHL), emicizumab, fitusiran, gene therapy (Hemgenix) |
| 11. Prognosis | Normal life expectancy, prevention of arthropathy, inhibitor management |
| 12. Prevention | Genetic counseling, carrier testing, prenatal diagnosis, primary prophylaxis |
| 13. References | 10 major international guidelines and original articles |
"Plasma Thromboplastin Component (PTC)" is a historical name born in the golden age of blood coagulation research in the 1950s. To understand this name, one must first look at the context of coagulation physiology research at the time.
In the late 1940s to early 1950s, researchers increasingly recognized that blood coagulation goes through complex steps beyond the simple conversion of fibrinogen to fibrin. In particular, the concept of 'thromboplastin' drew attention. At the time, thromboplastin referred to the factor complex in plasma required to convert prothrombin to thrombin, and it began to be known that several protein components in plasma are involved in forming this complex. In other words, the concept formed that thromboplastin is not a single substance but a complex activity generated by the cooperation of several 'components' in plasma.
In 1953, Macfarlane and Biggs published the Thromboplastin Generation Test (TGT), which put this concept into practice as a test method. The TGT evaluated the ability to generate thromboplastin by cross-supplementing each component of the patient's plasma (adsorbed plasma, serum, platelets, etc.). This test made it possible to distinguish several coagulation disorders, including hemophilia A and hemophilia B, and it became the key tool for diagnosing hemophilia in the 1950s.
1952 is the year in which two groundbreaking discoveries in the history of hemophilia B were made almost simultaneously. Two research groups in the United Kingdom and the United States independently discovered the same disease and gave it different names.
Aggeler PM, White SG, Glendening MB, Page EW, Leake TB, Bates G of the University of California, San Francisco (UCSF) described "a new disease similar to but distinct from hemophilia" in the Proceedings of the Society for Experimental Biology and Medicine in 1952 (Proc Soc Exp Biol Med. 1952;79(4):692-694). Emphasizing that the deficient factor was a 'component' contributing to thromboplastin generation in plasma, they named it Plasma Thromboplastin Component (PTC) deficiency.
In the same year, Biggs R, Douglas AS, Macfarlane RG and colleagues at the University of Oxford in the United Kingdom published a study in the British Medical Journal that included the case of a 5-year-old boy named Stephen Christmas and proposed the name Christmas disease. The name Christmas factor arose from the patient's surname, together with the coincidence that the paper was published in the December 27 issue of the BMJ, just before Christmas.
Both research groups demonstrated that deficiency of a factor different from the then-known antihemophilic factor (AHF, i.e., FVIII) was the cause of bleeding. This was because, in cross-supplementation experiments using the TGT, each group's patient plasma could correct the plasma of hemophilia A patients. This established that there are at least two independent types of X-linked recessive bleeding disorder.
For several years afterward, the two names PTC deficiency and Christmas disease were used interchangeably in the literature. Christmas disease tended to be used more in Europe and PTC deficiency more in the United States, but the need for an internationally unified name emerged.
From 1954, the international committee on the nomenclature of coagulation factors, the predecessor of the International Society on Thrombosis and Haemostasis (ISTH), began adopting a Roman numeral nomenclature system for plasma coagulation factors. Under this system, the then-known coagulation factors were numbered in order, starting with Factor I (fibrinogen), according to order of discovery and consensus. Christmas factor/PTC was confirmed as Factor IX in this system, and accordingly the official name of the disease was also standardized as hereditary factor IX deficiency or hemophilia B.
After the introduction of the Roman numeral system, the term PTC deficiency gradually receded from clinical practice, and hemophilia B and hereditary factor IX deficiency became established as the standard names. Nevertheless, the name PTC deficiency remains as a historical record in various official documents, including the ICD-10 classification system, and functions as an important historical term when reading 1950s medical literature or referring to research of that era.
The Macfarlane-Biggs thromboplastin generation test (TGT) was the key tool for diagnosing hemophilia and distinguishing its subtypes in the 1950s–60s. By identifying which component of the patient's plasma was deficient on the TGT, it was possible to distinguish FVIII deficiency (hemophilia A) from FIX deficiency (hemophilia B, PTC deficiency). However, the TGT was technically complex and difficult to standardize. After the 1960s, as measurement of individual coagulation factor activities (FVIII:C, FIX:C, etc.) became possible, the TGT was gradually replaced in clinical practice and is now rarely used.
The cloning of human FIX cDNA by Kurachi and Davie in 1982 provided a decisive foundation for understanding the structure and function of PTC (=FIX) at the molecular level. Since then, the treatment of hemophilia B has advanced remarkably, from F9 gene mutation analysis and the development of recombinant FIX products (FDA approval of BeneFIX in 1997) to extended half-life products and, in 2022, AAV vector-based gene therapy (etranacogene dezaparvovec, FDA approval of Hemgenix). At the starting point of this entire journey lies the historical name 'PTC deficiency' given by Aggeler et al. in 1952.
Plasma thromboplastin component deficiency (PTC deficiency, hemophilia B) is caused by mutations in the F9 gene (Xq27.1) and is inherited in an X-linked recessive manner. The F9 gene is located at 27.1 on the long arm of the X chromosome, and various mutations of this gene result in reduced synthesis, impaired secretion, or functional defects of the FIX protein.
The types of F9 gene mutations are diverse. Missense mutations account for about 84% of the total; some of these impair only protein function (CRM+), while others also reduce protein stability. Deletions account for about 11% of the total, and the more extensive the deletion, the higher the risk of a severe phenotype and inhibitor development. Frameshift mutations and nonsense mutations completely block the synthesis of functional FIX protein, causing severe hemophilia. Promoter region mutations cause the FIX Leyden phenotype, which shows a unique course of spontaneous recovery from severe disease in childhood to mild disease after puberty.
De novo mutations occur in about 30% of all patients with hemophilia B, in which case the disease can develop even without a family history. Therefore, hemophilia B should be included in the differential diagnosis even in males with a bleeding tendency and no family history.
The F9 gene is located at 27.1 on the long arm of the X chromosome (Xq27.1), with a total size of about 34 kilobase pairs (kb), and consists of 8 exons. This gene encodes a vitamin K-dependent serine protease precursor (zymogen) of 415 amino acids in the mature FIX protein, with a molecular weight of about 55kDa, which is synthesized mainly in hepatocytes.
The gene size of F9 (34kb, 8 exons) is markedly smaller than that of F8 (186kb, 26 exons), making it relatively easy to load the entire FIX expression cassette into an AAV vector. This is one of the important technical factors that allowed hemophilia B to achieve clinical success in gene therapy before hemophilia A.
The domain structure of the FIX protein is arranged, from the N-terminus, in the order signal peptide → propeptide → Gla domain → EGF-1 domain → EGF-2 domain → activation peptide → serine protease (SP) domain. The 10~12 glutamic acid residues of the Gla domain are converted to γ-carboxyglutamic acid (Gla) by vitamin K-dependent carboxylase (GGCX), which is essential for binding to phospholipid membranes.
The risk of inhibitor (anti-FIX antibody) development is related to the mutation type. The risk of inhibitor development is high in patients with large deletions, nonsense mutations, or severe frameshift variants (mainly CRM- phenotype), and relatively low with missense mutations (including CRM+). The incidence of inhibitors in hemophilia B overall is about 3~5%.
The prevalence of hemophilia B (PTC deficiency) is about 1/25,000~30,000 male births, about 5 times rarer than hemophilia A (1/5,000~10,000). Worldwide, there are estimated to be about 160,000 patients with hemophilia B. In Korea, about 750 patients with hemophilia B are registered in the Korea Hemophilia Foundation database (KBDR).
The severity distribution is known to be about 30% severe (FIX:C less than 1%), about 30% moderate (FIX:C 1~5%), and about 40% mild (FIX:C 5~40%). In mild patients, diagnosis is not uncommonly delayed until adulthood.
No specific differences in prevalence by race or region have been reported, but certain variants (such as FIX Leyden) are observed relatively more often in certain populations. The proportion of de novo mutations is known to be about 30%.
FIX (PTC) is activated to FIXa in the intrinsic coagulation pathway (internal tenase pathway) by FXIa, or by the tissue factor-FVIIa complex of the extrinsic pathway. FIXa forms the intrinsic tenase complex together with FVIIIa (cofactor), calcium ions (Ca²⁺), and a negatively charged phospholipid membrane surface, and this complex activates FX to FXa.
FX activation is essential for FXa to form the prothrombinase complex with FVa and convert prothrombin to thrombin, and thrombin polymerizes fibrinogen into fibrin to form a stable clot. In FIX (PTC) deficiency, assembly of this intrinsic tenase complex is impossible or greatly reduced, leading to insufficient FXa generation and consequently reduced thrombin generation, resulting in hemostatic failure.
The efficiency of tenase complex formation varies with the degree of FIX deficiency, which determines the degree of bleeding tendency. In severe deficiency with FIX:C less than 1%, spontaneous joint bleeding and muscle hematomas occur repeatedly; in moderate deficiency with FIX:C 1~5%, excessive bleeding after trauma occurs; and in mild deficiency with 5~40%, abnormal bleeding tends to appear only with strong provoking factors such as surgery or tooth extraction.
The clinical symptoms of hemophilia B (PTC deficiency) are determined by the FIX:C level. In severe patients (FIX:C less than 1%), the most characteristic symptom is hemarthrosis. Intra-articular bleeding occurs repeatedly, spontaneously or with minor trauma, and the most commonly affected joints are the knees, elbows, and ankles. Recurrent hemarthrosis leads to chronic hemophilic arthropathy with synovial hypertrophy, cartilage destruction, and bone erosion, which greatly affects quality of life.
Muscle hematoma is also common in severe hemophilia B. In particular, iliopsoas hematoma is clinically important because it can cause groin pain and flexion deformity and sensory abnormalities due to femoral nerve compression. Intracranial hemorrhage can be fatal, and the importance of early diagnosis is emphasized especially in the neonatal period and childhood.
In moderate patients (FIX:C 1~5%), spontaneous bleeding occurs occasionally but less frequently than in severe disease. Excessive bleeding after severe trauma or surgery is the main symptom, and intermittent hemarthrosis may occur. In mild patients (FIX:C 5~40%), spontaneous bleeding during daily life is rare, and abnormal bleeding typically appears with significant bleeding-provoking stimuli such as tooth extraction, surgery, or trauma. In mild patients, diagnosis is often not made until adulthood.
In female carriers as well, FIX:C may fall below the lower limit of normal (about 50%) due to skewed X-chromosome inactivation (lyonization), in which case symptoms such as menorrhagia, postpartum hemorrhage, and excessive postoperative bleeding may occur.
The main laboratory signs of hemophilia B (PTC deficiency) are as follows. Isolated prolongation of APTT (activated partial thromboplastin time) is the most characteristic laboratory finding. PT (prothrombin time), platelet count, and bleeding time are normal. FIX:C is decreased, and its degree corresponds to the severity classification. The main difference from hemophilia A is that FVIII:C is normal and only FIX:C is decreased.
An inhibitor is a neutralizing anti-FIX antibody that can develop in patients exposed to FIX replacement therapy. The incidence of inhibitors in hemophilia B is about 3~5%, markedly lower than in hemophilia A (25~30%). However, when an inhibitor develops in hemophilia B, treatment can become particularly difficult. In hemophilia B patients with inhibitors, the efficacy of immune tolerance induction (ITI) is lower than in hemophilia A, and anaphylactic reactions or nephrotic syndrome have been reported during ITI attempts, so caution is needed.
On physical examination, findings of hemophilic arthropathy such as joint swelling, limited range of motion, and joint deformity due to recurrent joint bleeding may be observed. Muscle hematomas present with local swelling and tenderness, and in iliopsoas hematoma, a characteristic flexed posture (maintaining hip flexion) may appear.
The standard algorithm for screening for hemophilia B (PTC deficiency) consists of the following steps. Step 1: APTT measurement — prolonged APTT, normal PT, and normal platelet count suggest a deficiency in the intrinsic coagulation pathway. Step 2: Measurement of individual factor activity — if FVIII:C is normal and FIX:C is decreased, hemophilia B is diagnosed. Step 3: F9 gene analysis — confirmation by mutation identification through Sanger or NGS, and determination of the molecular type. Step 4: Inhibitor testing — the presence and titer of inhibitors are determined by the Bethesda assay or the Nijmegen modification.
There is an important caveat in neonatal screening. In the neonatal period, levels of vitamin K-dependent coagulation factors (FII, FVII, FIX, FX) are physiologically lower than the adult reference range. In particular, FIX is only 30~50% of adult levels until 6 months of age, so even if FIX:C is measured low in the neonatal period, retesting after 6 months of age is required to confirm hemophilia B. However, when there is a known family history, the diagnosis can be confirmed by performing F9 gene analysis immediately after birth.
In female carriers, FIX:C is often measured at around 50%, but some show lower values (less than 30%) due to skewed X-chromosome inactivation. F9 gene analysis is the most reliable method for carrier diagnosis.
The diagnosis of hemophilia B (PTC deficiency) is made by combining clinical and laboratory criteria. Clinical criteria include a bleeding history (spontaneous bleeding, joint bleeding, excessive postoperative bleeding, etc.) and family history (X-linked recessive pattern). Laboratory criteria are basically prolonged APTT, normal PT, and decreased FIX:C (less than 40%).
Severity classification according to the FIX:C level is as follows: severe FIX:C < 1%, moderate FIX:C 1~5%, mild FIX:C 5~40%. Identifying the specific mutation by F9 gene analysis enables confirmation, prediction of severity, assessment of inhibitor risk, support for carrier testing, and prenatal diagnosis.
When inhibitors develop, those below 5 Bethesda units (BU) are classified as low-titer and those of 5 or more as high-titer inhibitors. When an inhibitor is present, in planning treatment, bypassing agents (activated prothrombin complex concentrate, aPCC, or recombinant activated FVII, rFVIIa) are used instead of FIX concentrates, or emicizumab or fitusiran is considered.
Treatment of hemophilia B (PTC deficiency) is broadly divided into on-demand therapy and prophylaxis. Prophylaxis is the regular administration of FIX concentrates to prevent joint bleeding and the resulting hemophilic arthropathy, and is currently recommended as the standard of care for patients with severe and moderate hemophilia B.
Standard half-life (SHL) FIX products include the recombinant FIX products BeneFIX (nonacog alfa, Pfizer) and Rixubis (nonacog gamma, Takeda). The half-life of FIX is about 18~24 hours, and it is administered by intravenous injection 2~3 times a week. Extended half-life (EHL) FIX products can markedly reduce injection frequency: Alprolix (eftacog beta, FIX-Fc fusion protein, Sanofi, half-life about 82 hours, administered once weekly or every other week), Idelvion (albutrepenonacog alfa, FIX-albumin fusion, CSL Behring, half-life about 104 hours, administered once weekly to once every 2 weeks), and Rebinyn (nonacog beta pegol, PEG-FIX, Novo Nordisk, administered once weekly).
Emicizumab (Hemlibra) is a bispecific antibody that mimics FVIIIa function; its application in hemophilia B is considered in patients with inhibitors or in situations where access to FIX products is difficult. It is administered by subcutaneous injection and can be given once weekly, every other week, or once every 4 weeks. Fitusiran (Alhemo) is an siRNA therapy targeting antithrombin that can be used in both hemophilia A and B and is administered by subcutaneous injection once a month.
Gene therapy is achieving clinical success in hemophilia B. After the pioneering clinical study by Nathwani et al. (AAV8-FIX) was published in 2011, in November 2022 the FDA approved etranacogene dezaparvovec (Hemgenix, CSL Behring) as the first gene therapy for hemophilia B. Hemgenix is an AAV5 vector carrying the FIX Padua variant (p.Arg338Leu), aiming for sustained FIX expression after a single intravenous injection. In clinical studies, FIX:C was maintained at a median of 40% or more, and the annual number of bleeds decreased substantially. In patients with inhibitors, the bypassing agents NovoSeven (eptacog alfa, rFVIIa) or FEIBA (aPCC) are used to treat bleeding.
In the modern treatment environment, the prognosis of patients with hemophilia B (PTC deficiency) has improved greatly. When prophylaxis is systematically implemented, life expectancy has approached a level equivalent to that of the general population, and sudden death due to intracranial hemorrhage has also decreased markedly.
Chronic hemophilic arthropathy was a major cause of morbidity in generations before prophylaxis was introduced, but preventing joint damage through early primary prophylaxis is now the standard. When joint damage has already progressed, physical therapy, arthroscopy, or joint replacement may be required.
Although the incidence of inhibitors is low at 3~5%, when an inhibitor develops, treatment becomes complicated and bleeding control becomes difficult. When ITI is attempted in hemophilia B patients with inhibitors, there is a risk of anaphylaxis and nephrotic syndrome, so caution is needed. The introduction of non-factor replacement therapies such as emicizumab and fitusiran has expanded treatment options for patients with inhibitors. As gene therapy enters the stage of clinical application, the long-term prognosis of hemophilia B is expected to improve further.
Prevention of hemophilia B (PTC deficiency) takes place on two levels: genetic prevention and clinical prevention of bleeding. Genetic counseling should be offered to all families of patients with hemophilia B, providing sufficient information about the X-linked recessive inheritance pattern, the possibility of bleeding in female carriers, and reproductive options (prenatal diagnosis after natural conception, in vitro fertilization with PGT, etc.).
Carrier testing is performed in female first-degree relatives (mother, sisters, daughters) of patients with hemophilia B, and F9 gene analysis is the most reliable method. When FIX:C is low in a female carrier (especially less than 50%), a FIX replacement plan should be established before surgery or delivery. Prenatal diagnosis can be performed by chorionic villus sampling (CVS) at 11~14 weeks of gestation or amniocentesis at 15~18 weeks. Preimplantation genetic testing (PGT) is combined with IVF to determine whether the embryo has the hemophilia B genetic abnormality, and is optionally available.
Primary prophylaxis means starting regular FIX infusions before the first spontaneous joint bleed or before age 2, and is strongly recommended for severe and moderate patients to prevent hemophilic arthropathy. The introduction of EHL products has made it easier to reduce injection frequency and maintain high trough levels. Before any invasive procedure, a FIX replacement plan should be established in advance in collaboration with a hemophilia specialist, and the use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided as much as possible.